Treatments

The following database contains products that have been granted orphan status, or have been market approval in the EU or the USA.

You can filter the content by clicking on the titles: Product, Indication, Sponsor and Date. Clicking once, will filter the column alphabetically from A – Z and a second click on the same title will filter from Z – A.

Become a Partner.

Country Product Indication Sponsor Date
Antithrombin III (human) For replacement therapy in congenital deficiency of AT-III for prevention and treatment of thrombosis and pulmonary emboli Bayer Corporation;Pharmaceutical Division, Biological Products, 400 Morgan Lane;New Haven, Connecticut, 06516 November 26, 1984
Iobenguane Sulfate I 131 For use as a diagnostic adjunct in patients with pheochromocytoma University of Michigan;UH B1 H410/0028, 1500 E. Medical Center Drive;Ann Arbor, Michigan, 48109 November 14, 1984
Antimelanoma Antibody XMMME-001-DTPA 111 Indium Diagnostic use in imaging systemic and nodal melanoma metastasis Xoma Corporation;2910 Seventh Street;Berkeley, California, 94710 November 14, 1984
Antimelanoma Antibody XMMME-001-RTA Stage III melanoma not amenable to surgical resection Xoma Corporation;2910 Seventh Street;Berkeley, California, 94710 November 14, 1984
Selegiline HCl As an adjuvant to levodopa and carbidopa treatment of idiopathic Parkinson's disease (paralysis agitans), postencephalitic Parkinsonism, and symptomatic Parkinsonism Somerset Pharmaceuticals, Inc.;400 Morris Ave., Suite 7s;Denville, New Jersey, 07834 November 7, 1984
Potassium citrate 1. Prevention of calcium renal stones in patients with hypocitraturia 2. For avoidance of the complication of calcium stone formation in patients with uric lithiasis. University of Texas Health Science Center at Dallas;5323 Harry Hines Blvd;Dallas, Texas, 75235 November 1, 1984
Digoxin immune FAB (Ovine) Potentially life threatening digitalis intoxication in patients who are refractory to management by conventional therapy Glaxo Wellcome Inc.;5 Moore Drive;Research Triangle Park, North Carolina, 27709 November 1, 1984
L-5 Hydroxytrytophan Postanoxic intention myoclonus Watson Laboratories, Inc.;33 Ralph Avenue, P.O. Box 30;Copiaque, New York, 11726 November 1, 1984
Teniposide Refractory childhood acute lymphocytic leukemia Bristol-Myers Squibb Pharmaceutical Research Institute;5 Research Parkway, P.O. Box 5100;Wallingford, Connecticut, 06492 November 1, 1984
Potassium citrate Prevention of uric acid nephrolithiasis University of Texas Health Science Center at Dallas;5323 Harry Hines Blvd;Dallas, Texas, 75235 November 1, 1984
Urogastrone For acceleration of corneal epithelial regeneration and healing of stromal incisions from corneal transplant surgery Chiron Vision;500 Iolab Drive;Claremont, California, 91711 November 1, 1984
Potassium citrate Prevention of calcium renal stones in patients with hypocitraturia University of Texas Health Science Center at Dallas;5323 Harry Hines Blvd;Dallas, TX, 75235 November 1, 1984
Potassium citrate For avoidance of the complication of calcium stone formation in patients with uric lithiasis University of Texas Health Science Center at Dallas;5323 Harry Hines Blvd;Dallas, TX, 75235 November 1, 1984
Pentamidine isethionate Pneumocystis carinii pneumonia Aventis Behring L.L.C.;1020 First Avenue, PO Box 61501;King of Prussia, Pennsylvania, 19406 October 29, 1984
Epoprostenol Replacement of heparin in patients requiring hemodialysis and who are at increased risk of hemorrhage Upjohn Company;301 Henrietta Street;Kalamazoo, Michigan, 49001 October 29, 1984
Cyproterone acetate Severe hirsutism Berlex Laboratories, Inc.;300 Fairfield Road;Wayne, New Jersey, 07470 October 26, 1984
Spiramycin Cryptosporidiosis Rhone-Poulenc Rorer Pharmaceuticals;500 Arcola Road;Collegeville, Pennsylvania, 19426 October 17, 1984
Quinacrine hydrochloride For prevention of recurrence of pneumothorax in patients at high risk of recurrence Lyphomed, Inc.;; October 17, 1984
Chenodiol For patients with radiolucent stones in well opacifying gallbladders, in whom elective surgery would be undertaken except for the presence of increased surgical risk due to systemic disease or age Solvay;901 Sawyer Road;Marietta, Georgia, 30062 September 21, 1984
Iodine 131 6B-iodomethyl-19-norcholesterol For use in adrenal cortical imaging David E. Kuhl, M.D.;University of Michigan Medical Center/1500 E. Med., B1G412 /0028 University Hospital;Ann Arbor, Michigan, 48109 August 1, 1984
Levocarnitine Primary carnitine deficiency Leadiant Biosciences, Inc.;9841 Washingtonian Blvd, Suite 500;Gaithersburg, Maryland, 20878 July 26, 1984
Clofazimine Leprosy Novartis Pharmaceutical Corporation;59 Route 10;East Hanover, New Jersey, 07936 June 11, 1984
Monooctanoin For dissolution of cholesterol gallstones retained in the common bile duct Ethitek Pharmaceuticals, Inc.;7855 Gross Point Road, Unit L;Skokie, Illinois, 60077 May 30, 1984
Pegademase bovine Adenosine deaminase deficiency Sigma-tau Pharmaceuticals, Inc.;9841 Washingtonian Blvd, Suite 500;Gaithersburg, Maryland, 20878 May 29, 1984
Succimer Lead poisoning in children Bock Pharmacal Company;P.O. Box 419056;Saint Louis, Missouri, 63141 May 9, 1984